Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.1.1.348 - mRNA m6A methyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Spontaneous
The involvement of eukaryotic initiation factor 5A in trophoblast cell function.
Adenocarcinoma
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1.
Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Adenocarcinoma of Lung
m6A RNA Methylation Regulators Act as Potential Prognostic Biomarkers in Lung Adenocarcinoma.
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs.
The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.
The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by ?-elemene.
Adenomyosis
m6A RNA Methylation Regulators Contribute to Eutopic Endometrium and Myometrium Dysfunction in Adenomyosis.
Alzheimer Disease
Altered Expression of the m6A Methyltransferase METTL3 in Alzheimer's Disease.
Aortic Aneurysm, Abdominal
METTL3 Induces AAA Development and Progression by Modulating N6-Methyladenosine-Dependent Primary miR34a Processing.
Aortic Valve Stenosis
Factors influencing osteogenic differentiation of human aortic valve interstitial cells.
Arthritis, Rheumatoid
Decreased ALKBH5, FTO, and YTHDF2 in Peripheral Blood Are as Risk Factors for Rheumatoid Arthritis.
METTL3 Attenuates LPS-Induced Inflammatory Response in Macrophages via NF-?B Signaling Pathway.
METTL3 Promotes Activation and Inflammation of FLSs Through the NF-?B Signaling Pathway in Rheumatoid Arthritis.
Asthenozoospermia
Increased N6-methyladenosine in Human Sperm RNA as a Risk Factor for Asthenozoospermia.
Atherosclerosis
METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications.
METTL14 mediated m6A modification to LncRNA ZFAS1/ RAB22A: A novel therapeutic target for atherosclerosis.
METTL3-dependent N6-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium.
Bacterial Infections
N6-Adenosine Methylation of Socs1 mRNA Is Required to Sustain the Negative Feedback Control of Macrophage Activation.
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation.
Bone Resorption
Circ_0008542 in osteoblast exosomes promotes osteoclast-induced bone resorption through m6A methylation.
YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-?B and MAPK signaling pathways.
Breast Neoplasms
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.
CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression.
Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Metformin exhibits antiproliferation activity in breast cancer via miR-483-3p/METTL3/m6A/p21 pathway.
METTL14 promotes the migration and invasion of breast cancer cells by modulating N6?methyladenosine and hsa?miR?146a?5p expression.
METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
N6 -Methyladenosine Regulates mRNA Stability and Translation Efficiency of KRT7 to Promote Breast Cancer Lung Metastasis.
N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation.
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Carcinogenesis
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Detailed modeling of positive selection improves detection of cancer driver genes.
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Downregulation of N
Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis.
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma.
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
m6A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways.
m6A-dependent glycolysis enhances colorectal cancer progression.
Methyltransferase-like 3-induced N6-methyladenosine upregulation promotes oral squamous cell carcinoma by through p38.
METTL14 facilitates global genome repair and suppresses skin tumorigenesis.
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE.
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
METTL3 Promotes mRNA Translation to Drive Tumorigenesis.
METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway.
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.
METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers.
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Novel insights into the interplay between m6A modification and noncoding RNAs in cancer.
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target.
Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives.
YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Carcinoma
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Identification of METTL14 in Kidney Renal Clear Cell Carcinoma Using Bioinformatics Analysis.
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.
METTL3 enhances cell adhesion through stabilizing integrin ?1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ?Np63.
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.
MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Prognostic Roles of N6-Methyladenosine METTL3 in Different Cancers: A System Review and Meta-Analysis.
Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma.
Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma.
SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation.
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer.
Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma.
[Knockdown of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) inhibits cell proliferation and promotes apoptosis in cervical cancer cells].
Carcinoma, Hepatocellular
Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
Correction to: YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
Downregulation of N
Identification of METTL3 as an Adverse Prognostic Biomarker in Hepatocellular Carcinoma.
METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner.
METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.
METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma.
METTL3 promotes the progression of hepatocellular carcinoma through m6A-mediated up-regulation of microRNA-873-5p.
MicroRNA-145 Modulates N(6)-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N(6)-Methyladenosine Binding YTH Domain Family 2 Protein.
RNA m6 A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy.
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.
The Effect of m6A Methylation Regulatory Factors on the Malignant Progression and Clinical Prognosis of Hepatocellular Carcinoma.
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives.
USP48 Is Upregulated by Mettl14 to Attenuate Hepatocellular Carcinoma via Regulating SIRT6 Stabilization.
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.
[METTL14 as a predictor of postoperative survival outcomes of patients with hepatocellular carcinoma].
Carcinoma, Non-Small-Cell Lung
MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
Carcinoma, Ovarian Epithelial
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Carcinoma, Renal Cell
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.
Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma.
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
Carcinoma, Squamous Cell
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ?Np63.
The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer.
Cardiomegaly
De-ubiquitination of p300 by USP12 Critically Enhances METTL3 Expression and Ang II-induced cardiac hypertrophy.
YTHDF2 alleviates cardiac hypertrophy via regulating Myh7 mRNA decoy.
Cardiovascular Diseases
RNA Modification by m6A Methylation in Cardiovascular Disease.
Cataract
N6-Methyladenosine METTL3 Modulates the Proliferation and Apoptosis of Lens Epithelial Cells in Diabetic Cataract.
Colitis
A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA m6A Methyltransferase Component METTL14 in T Cells.
Colonic Neoplasms
An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells.
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
Colorectal Neoplasms
Knockdown of RNA N6-methyladenosine methyltransferase METTL3 represses Warburg effect in colorectal cancer via regulating HIF-1?.
LINC01605, regulated by the EP300-SMYD2 complex, potentiates the binding between METTL3 and SPTBN2 in colorectal cancer.
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
m6A methyltransferase METTL3 suppresses colorectal cancer proliferation and migration through p38/ERK pathways.
Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N6 -methyladenosine methylation through methyltransferase-like 14.
Methyltransferase like 3 promotes colorectal cancer proliferation by stabilizing CCNE1 mRNA in an m6A-dependent manner.
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators.
RNA m6A methyltransferase METTL3 promotes colorectal cancer cell proliferation and invasion by regulating Snail expression.
RNA N6-Methyladenosine Methyltransferase METTL3 Facilitates Colorectal Cancer by Activating the m6A-GLUT1-mTORC1 Axis and Is a Therapeutic Target.
The differentiation of colorectal cancer is closely relevant to m6A modification.
Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Upregulation of circular and linear METTL3 and USP3 in colorectal cancer.
Corneal Neovascularization
Role of METTL3-Dependent N6-Methyladenosine mRNA Modification in the Promotion of Angiogenesis.
COVID-19
Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication.
METTL3 regulates viral m6A RNA modification and host cell innate immune responses during SARS-CoV-2 infection.
Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication.
Cysts
A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease.
Cytomegalovirus Infections
The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
Diabetes Mellitus
Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8.
Diabetes Mellitus, Type 2
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Diabetic Nephropathies
METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of ?-klotho.
Diabetic Retinopathy
Overexpression of METTL3 attenuates high-glucose induced RPE cell pyroptosis by regulating miR-25-3p/PTEN/Akt signaling cascade through DGCR8.
Disorders of Sex Development
Sex differences in autophagy-mediated diseases: toward precision medicine.
Endometrial Neoplasms
Effects of m6A RNA methylation regulators on endometrial cancer.
Immune infiltration-related N6-methyladenosine RNA methylation regulators influence the malignancy and prognosis of endometrial cancer.
YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A.
Endometriosis
Inhibition of METTL3/m6A/miR126 promotes the migration and invasion of endometrial stromal cells in endometriosis.
Esophageal Neoplasms
METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway.
Network analysis of miRNA targeting m6A-related genes in patients with esophageal cancer.
Targeting SNHG3/miR-186-5p reverses the increased m6A level caused by platinum treatment through regulating METTL3 in esophageal cancer.
Esophageal Squamous Cell Carcinoma
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
METTL3-mediated m6A mRNA modification promotes esophageal cancer initiation and progression via Notch signaling pathway.
Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma.
Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
Gastrointestinal Neoplasms
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer.
Glioblastoma
ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism.
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma.
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
Glioma
A Risk Signature Consisting of Eight m6A Methylation Regulators Predicts the Prognosis of Glioma.
EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma.
Genetic variants in m6A modification core genes are associated with glioma risk in Chinese children.
m6A RNA Methylation Controls Proliferation of Human Glioma Cells by Influencing Cell Apoptosis.
METTL3 enhances the stability of MALAT1 with the assistance of HuR via m6A modification and activates NF-?B to promote the malignant progression of IDH-wildtype glioma.
METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m6A Dependent Manner.
Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.
N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma.
N?-Methyladenosine Landscape of Glioma Stem-Like Cells: METTL3 Is Essential for the Expression of Actively Transcribed Genes and Sustenance of the Oncogenic Signaling.
The Emerging Roles of RNA Modifications in Glioblastoma.
YTHDF2 correlates with tumor immune infiltrates in lower-grade glioma.
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-?B and promote the malignant progression of glioma.
Glucose Intolerance
Acute Deletion of METTL14 in ?-Cells of Adult Mice Results in Glucose Intolerance.
Heart Failure
The N6-Methyladenosine mRNA Methylase METTL3 Controls Cardiac Homeostasis and Hypertrophy.
Hematologic Neoplasms
Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion.
Hemorrhoids
MiR-4729 regulates TIE1 mRNA m6A modification and angiogenesis in hemorrhoids by targeting METTL14.
Hepatoblastoma
Cross talk between RNA N6-methyladenosine methyltransferase-like 3 and miR-186 regulates hepatoblastoma progression through Wnt/?-catenin signalling pathway.
m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma.
Polymorphisms in METTL3 gene and hepatoblastoma risk in Chinese children: A seven-center case-control study.
Herpesviridae Infections
N6-methyladenosine modification and the YTHDF2 reader protein play cell type specific roles in lytic viral gene expression during Kaposi's sarcoma-associated herpesvirus infection.
Hyperglycemia
METTL3 is required for maintaining ?-cell function.
Hypersensitivity
Methyltransferase-like 3 contributes to inflammatory pain by targeting TET1 in YTHDF2-dependent manner.
Hypertension
The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension.
Infections
Enterotoxigenic Escherichia coli infection promotes enteric defensin expression via FOXO6-METTL3-m6A-GPR161 signalling axis.
Knockdown of METTL3 inhibits enterovirus 71-induced apoptosis of mouse Schwann cell through regulation of autophagy.
Metal-Protein Nanoparticles Facilitate Anti-VSV and H1N1 Viruses Through the Coordinative Actions on Innate Immune Responses and METTL14.
N6-methyladenosine modifications enhance enterovirus 71 ORF translation through METTL3 cytoplasmic distribution.
N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA.
Targeting the m6A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication.
Infertility
The RNA m(6)A Reader YTHDF2 Is Essential for the Post-transcriptional Regulation of the Maternal Transcriptome and Oocyte Competence.
Influenza, Human
Metal-Protein Nanoparticles Facilitate Anti-VSV and H1N1 Viruses Through the Coordinative Actions on Innate Immune Responses and METTL14.
Insulin Resistance
m6A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes.
METTL3 inhibits hepatic insulin sensitivity via N6-methyladenosine modification of Fasn mRNA and promoting fatty acid metabolism.
METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice.
Intracranial Arteriovenous Malformations
N6-methyladenosine methyltransferase METTL3 affects the phenotype of cerebral arteriovenous malformation via modulating Notch signaling pathway.
Kidney Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Lentivirus Infections
RNA m6A methylation participates in regulation of postnatal development of the mouse cerebellum.
Leukemia
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
YTHDF2 is a potential target of AML1/ETO-HIF1? loop-mediated cell proliferation in t(8;21) AML.
YTHDF2 Is Required for Leukemia Stem Cells Function in AML.
Leukemia, Myeloid
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
Leukemia, Myeloid, Acute
Identification of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia.
Novel METTL3 Modulators for Treating Acute Myeloid Leukemia (AML).
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
Liver Neoplasms
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
Pending role of METTL14 in liver cancer.
RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail.
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Lung Neoplasms
Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma.
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
IL-37 Confers Anti-Tumor Activity by Regulation of m6A Methylation.
METTL3?mediated m6A modification of Bcl?2 mRNA promotes non?small cell lung cancer progression.
miR-338-5p inhibits cell growth and migration via inhibition of the METTL3/m6A/c-Myc pathway in lung cancer.
MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
miR-600 inhibits lung cancer via downregulating the expression of METTL3.
mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.
The m6A methyltransferase METTL3 contributes to Transforming Growth Factor-beta-induced epithelial-mesenchymal transition of lung cancer cells through the regulation of JUNB.
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
Lupus Erythematosus, Systemic
The study of METTL14, ALKBH5, and YTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus.
Lymphatic Metastasis
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
Melanoma
Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma.
m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy.
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade.
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation.
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
miR-302a-3p suppresses melanoma cell progression via targeting METTL3.
Proteome-wide Interrogation of Small GTPases Regulated by N6-Methyladenosine Modulators.
RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2.
Metabolic Syndrome
m6A Regulates Liver Metabolic Disorders and Hepatogenous Diabetes.
Microphthalmos
m6A writer complex promotes timely differentiation and survival of retinal progenitor cells in zebrafish.
Mouth Neoplasms
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
mrna m6a methyltransferase deficiency
A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA m6A Methyltransferase Component METTL14 in T Cells.
Acute Deletion of METTL14 in ?-Cells of Adult Mice Results in Glucose Intolerance.
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Interplay of m6A and H3K27 trimethylation restrains inflammation during bacterial infection.
METTL14 is essential for ?-cell survival and insulin secretion.
METTL3 and ALKBH5 oppositely regulate m6A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes.
Mettl3 Deficiency Sustains Long-Chain Fatty Acid Absorption through Suppressing Traf6-Dependent Inflammation Response.
METTL3 Induces AAA Development and Progression by Modulating N6-Methyladenosine-Dependent Primary miR34a Processing.
METTL3 Modulates Osteoclast Differentiation and Function by Controlling RNA Stability and Nuclear Export.
METTL3-dependent m6A modification programs T follicular helper cell differentiation.
N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma.
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation.
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function.
The RNA m(6)A Reader YTHDF2 Is Essential for the Post-transcriptional Regulation of the Maternal Transcriptome and Oocyte Competence.
The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
Mycoses
Fusarium infection alters the m6A-modified transcript landscape in the cornea.
Myocardial Infarction
Loss of m6A methyltransferase METTL3 promotes heart regeneration and repair after myocardial injury.
Silencing of METTL3 attenuates cardiac fibrosis induced by myocardial infarction via inhibiting the activation of cardiac fibroblasts.
Nasopharyngeal Carcinoma
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Neoplasm Metastasis
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.
Circular RNA circ_0001105 Inhibits Progression and Metastasis of Osteosarcoma by Sponging miR-766 and Activating YTHDF2 Expression.
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer.
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1.
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N6 -methyladenosine methylation through methyltransferase-like 14.
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner.
METTL14 Suppresses CRC Progression via Regulating N6-Methyladenosine-Dependent Primary miR-375 Processing.
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
METTL3 enhances cell adhesion through stabilizing integrin ?1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.
METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
N6 -Methyladenosine Regulates mRNA Stability and Translation Efficiency of KRT7 to Promote Breast Cancer Lung Metastasis.
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma.
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation.
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming.
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
The biological function of m6A reader YTHDF2 and its role in human disease.
The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma.
The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.
Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer.
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
Neoplasms
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer.
Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine-centre case-control study.
Author Correction: METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
Changes of N6-methyladenosine modulators promote breast cancer progression.
Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
CircMETTL3, upregulated in a m6A-dependent manner, promotes breast cancer progression.
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases.
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.
Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer.
Cross-talk among writers, readers, and erasers of m6A regulates cancer growth and progression.
Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma.
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Detailed modeling of positive selection improves detection of cancer driver genes.
Development and validation of a m6A RNA methylation regulators-based signature for predicting the prognosis of head and neck squamous cell carcinoma.
Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
Downregulation of N
Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
EBV epitranscriptome reprogramming by METTL14 is critical for viral-associated tumorigenesis.
Effect of N6-Methyladenosine Regulators on Progression and Prognosis of Triple-Negative Breast Cancer.
Effects of Quercetin on the Efficacy of Various Chemotherapeutic Drugs in Cervical Cancer Cells.
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer.
Expression patterns and prognostic value of m6A-related genes in colorectal cancer.
Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma.
HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Identification of a m6A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma.
Identification of pathology-specific regulators of m6A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine.
Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism.
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures.
m(6)A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination.
m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy.
m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
m6A methyltransferase METTL3 maintains colon cancer tumorigenicity by suppressing SOCS2 to promote cell proliferation.
m6A methyltransferase METTL3 promotes retinoblastoma progression via PI3K/AKT/mTOR pathway.
m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.
m6A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma.
m6A RNA methylation regulators have prognostic value in papillary thyroid carcinoma.
m6A RNA Methylation Regulators Participate in the Malignant Progression and Have Clinical Prognostic Value in Lung Adenocarcinoma.
Methyl CpG binding protein 2 promotes colorectal cancer metastasis by regulating N6 -methyladenosine methylation through methyltransferase-like 14.
Methyltransferase-like 3-induced N6-methyladenosine upregulation promotes oral squamous cell carcinoma by through p38.
METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.
METTL14 facilitates global genome repair and suppresses skin tumorigenesis.
METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study.
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
METTL14 Overexpression Promotes Osteosarcoma Cell Apoptosis and Slows Tumor Progression via Caspase 3 Activation.
METTL14 promotes the migration and invasion of breast cancer cells by modulating N6?methyladenosine and hsa?miR?146a?5p expression.
METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N(6) -methyladenosine-dependent primary MicroRNA processing.
METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
METTL3 and N6-Methyladenosine Promote Homologous Recombination-Mediated Repair of DSBs by Modulating DNA-RNA Hybrid Accumulation.
METTL3 enhances cell adhesion through stabilizing integrin ?1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma.
METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma.
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE.
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation.
METTL3 May Regulate Testicular Germ Cell Tumors Through EMT and Immune Pathways.
METTL3 mediated m6A modification plays an oncogenic role in cutaneous squamous cell carcinoma by regulating ?Np63.
METTL3 plays multiple functions in biological processes.
METTL3 polymorphisms and Wilms tumor susceptibility in Chinese children: A five-center case-control study.
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
METTL3 Promotes Esophageal Squamous Cell Carcinoma Metastasis Through Enhancing GLS2 Expression.
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.
METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
METTL3 promotes the progression of hepatocellular carcinoma through m6A-mediated up-regulation of microRNA-873-5p.
METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
METTL3 promotes the proliferation and invasion of esophageal cancer cells partly through AKT signaling pathway.
METTL3 Promotes the Proliferation and Mobility of Gastric Cancer Cells.
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
METTL3 promotes tumour development by decreasing APC expression mediated by APC mRNA N6-methyladenosine-dependent YTHDF binding.
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B.
Mettl3 regulates the proliferation, migration and invasion of glioma cells by inhibiting PI3K/Akt signaling pathway.
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
METTL3-induced UCK2 m6A hypermethylation promotes melanoma cancer cell metastasis via the WNT/?-catenin pathway.
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
METTL3-mediated m6A mRNA modification of FBXW7 suppresses lung adenocarcinoma.
METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells.
METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
METTL3-mediated RNA m6A hypermethylation promotes tumorigenesis and GH secretion of pituitary somatotroph adenomas.
METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.
METTL3/YTHDF2 m6A axis accelerates colorectal carcinogenesis through epigenetically suppressing YPEL5.
MicroRNA-145 Modulates N(6)-Methyladenosine Levels by Targeting the 3'-Untranslated mRNA Region of the N(6)-Methyladenosine Binding YTH Domain Family 2 Protein.
Mining for METTL3 inhibitors to suppress cancer.
miR-302a-3p suppresses melanoma cell progression via targeting METTL3.
Mobile element insertions and associated structural variants in longitudinal breast cancer samples.
mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.
Multiple Functions and Mechanisms Underlying the Role of METTL3 in Human Cancers.
N6-methyladenosine (m6A)-mediated messenger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma.
N6-methyladenosine demethyltransferase FTO-mediated autophagy in malignant development of oral squamous cell carcinoma.
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
N6-methyladenosine Modulates Nonsense-mediated mRNA Decay in Human Glioblastoma.
N6-Methyladenosine Regulators Are Involved in the Progression of and Have Clinical Impact on Breast Cancer.
N6-Methyladenosine RNA Methylation Regulator-Related Alternative Splicing (AS) Gene Signature Predicts Non-Small Cell Lung Cancer Prognosis.
N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer.
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
Novel insights into the m6A-RNA methyltransferase METTL3 in cancer.
Novel prognostic implications of YTH domain family 2 in resected hepatocellular carcinoma.
Overexpression of METTL3 associated with the metabolic status on 18F-FDG PET/CT in patients with Esophageal Carcinoma.
Pan-Cancer Prognostic, Immunity, Stemness, and Anticancer Drug Sensitivity Characterization of N6-Methyladenosine RNA Modification Regulators in Human Cancers.
Polymorphisms in METTL3 gene and hepatoblastoma risk in Chinese children: A seven-center case-control study.
Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation.
Prognostic Roles of N6-Methyladenosine METTL3 in Different Cancers: A System Review and Meta-Analysis.
Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma.
Regulation of telomere homeostasis and genomic stability in cancer by N 6-adenosine methylation (m6A).
RNA epigenetic modification: N6-methyladenosine.
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming.
RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail.
RNA m6A methyltransferase METTL3 promotes colorectal cancer cell proliferation and invasion by regulating Snail expression.
RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway.
RNA m6A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/?-catenin signaling.
RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma.
RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy.
RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2 dependent post-transcriptional silencing of SOCS2.
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Roles of METTL3 in cancer: mechanisms and therapeutic targeting.
Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
Silencing of methyltransferase-like 3 inhibits oesophageal squamous cell carcinoma.
SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma.
SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function.
SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs.
Systematic Analyses of the Role of the Reader Protein of N 6-Methyladenosine RNA Methylation, YTH Domain Family 2, in Liver Hepatocellular Carcinoma.
Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia.
The biological function of m6A reader YTHDF2 and its role in human disease.
The Cancer Genome Atlas (TCGA) based m6A methylation-related genes predict prognosis in hepatocellular carcinoma.
The contribution of YTHDF2 gene rs3738067 A>G to the Wilms tumor susceptibility.
The Emerging Roles of RNA m6A Methylation and Demethylation as Critical Regulators of Tumorigenesis, Drug Sensitivity, and Resistance.
The Emerging Roles of RNA Modifications in Glioblastoma.
The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth.
The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells.
The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.
The m6A Methyltransferase METTL14-Mediated N6-Methyladenosine Modification of PTEN mRNA Inhibits Tumor Growth and Metastasis in Stomach Adenocarcinoma.
The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis.
The m6A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m6A modification on SOX2.
The M6A methyltransferase METTL3: acting as a tumor suppressor in renal cell carcinoma.
The METTL3-m6A Epitranscriptome: Dynamic Regulator of Epithelial Development, Differentiation, and Cancer.
The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.
The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity.
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells.
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.
The role of N6-methyladenosine RNA methylation in the heat stress response of sheep (Ovis aries).
The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives.
Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
Upregulated METTL3 promotes metastasis of colorectal Cancer via miR-1246/SPRED2/MAPK signaling pathway.
Upregulation of METTL3 Expression Predicts Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma.
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
YTHDF2 correlates with tumor immune infiltrates in lower-grade glioma.
YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-?B and promote the malignant progression of glioma.
YTHDF2 inhibit the tumorigenicity of endometrial cancer via downregulating the expression of IRS1 methylated with m6A.
YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation.
YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma.
YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma.
YTH domain family 2 promotes lung cancer cell growth by facilitating 6-phosphogluconate dehydrogenase mRNA translation.
[METTL14 as a predictor of postoperative survival outcomes of patients with hepatocellular carcinoma].
Neoplasms, Germ Cell and Embryonal
METTL3 May Regulate Testicular Germ Cell Tumors Through EMT and Immune Pathways.
N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readers.
Neuroblastoma
Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: A nine-centre case-control study.
METTL14 Gene Polymorphisms Confer Neuroblastoma Susceptibility: An Eight-Center Case-Control Study.
Non-alcoholic Fatty Liver Disease
METTL3-m6A-Rubicon axis inhibits autophagy in nonalcoholic fatty liver disease.
Obesity
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
METTL3 is essential for postnatal development of brown adipose tissue and energy expenditure in mice.
Resveratrol Attenuates High-Fat Diet Induced Hepatic Lipid Homeostasis Disorder and Decreases m6A RNA Methylation.
RNA epigenetic modification: N6-methyladenosine.
Osteoarthritis
METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response.
METTL3 promotes experimental osteoarthritis development by regulating inflammatory response and apoptosis in chondrocyte.
Osteoporosis
m6A Methylation of Precursor-miR-320/RUNX2 Controls Osteogenic Potential of Bone Marrow-Derived Mesenchymal Stem Cells.
Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis.
Regulatory Role of RNA N6-Methyladenosine Modification in Bone Biology and Osteoporosis.
Osteosarcoma
Circular RNA circ_0001105 Inhibits Progression and Metastasis of Osteosarcoma by Sponging miR-766 and Activating YTHDF2 Expression.
m6A-dependent up-regulation of DRG1 by METTL3 and ELAVL1 promotes growth, migration, and colony formation in osteosarcoma.
METTL14 Overexpression Promotes Osteosarcoma Cell Apoptosis and Slows Tumor Progression via Caspase 3 Activation.
Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2.
The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
Ovarian Neoplasms
FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2.
METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
METTL3 promotes the initiation and metastasis of ovarian cancer by inhibiting CCNG2 expression via promoting the maturation of pri-microRNA-1246.
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway.
METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway.
YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells.
Pancreatic Neoplasms
CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Downregulation of METTL14 increases apoptosis and autophagy induced by cisplatin in pancreatic cancer cells.
m6A Methyltransferase METTL14-Mediated Upregulation of Cytidine Deaminase Promoting Gemcitabine Resistance in Pancreatic Cancer.
Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.
The RNA m6A methyltransferase METTL3 promotes pancreatic cancer cell proliferation and invasion.
Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer.
Parkinsonian Disorders
Sex differences in autophagy-mediated diseases: toward precision medicine.
Pituitary Neoplasms
METTL3-mediated RNA m6A hypermethylation promotes tumorigenesis and GH secretion of pituitary somatotroph adenomas.
Pneumonia
METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2.
Polycystic Kidney, Autosomal Dominant
A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease.
Pre-Eclampsia
Upregulation of METTL3 expression and m6A RNA methylation in placental trophoblasts in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The study of METTL3 and METTL14 expressions in childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.
Prostatic Neoplasms
Comprehensive analysis of m6A regulators prognostic value in prostate cancer.
Downregulation of N
m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance.
RNA m6A Methyltransferase METTL3 Promotes The Growth Of Prostate Cancer By Regulating Hedgehog Pathway.
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Pulmonary Arterial Hypertension
The m6A methyltransferase METTL3 promotes hypoxic pulmonary arterial hypertension.
Pulmonary Disease, Chronic Obstructive
m6A RNA methylation regulators could contribute to the occurrence of chronic obstructive pulmonary disease.
The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
Pulmonary Fibrosis
m6A modification regulates lung fibroblast-to-myofibroblast transition through modulating KCNH6 mRNA translation.
Rectal Neoplasms
M6A "Writer" Gene METTL14: A Favorable Prognostic Biomarker and Correlated With Immune Infiltrates in Rectal Cancer.
Prognostic Implication of the m6A RNA Methylation Regulators in Rectal Cancer.
Reperfusion Injury
METTL3 contributes to renal ischemia-reperfusion injury by regulating Foxd1 methylation.
The N6-methyladenosine mRNA methylase METTL14 promotes renal ischemic reperfusion injury via suppressing YAP1.
Retinoblastoma
m6A methyltransferase METTL3 promotes retinoblastoma progression via PI3K/AKT/mTOR pathway.
Seminoma
METTL3 potentiates resistance to cisplatin through m6 A modification of TFAP2C in seminoma.
The m6A methyltransferase METTL3 regulates autophagy and sensitivity to cisplatin by targeting ATG5 in seminoma.
Severe Acute Respiratory Syndrome
Methyltransferase-like 3 Modulates Severe Acute Respiratory Syndrome Coronavirus-2 RNA N6-Methyladenosine Modification and Replication.
Spinal Cord Injuries
Epitranscriptomic m6A regulation following spinal cord injury.
Squamous Cell Carcinoma of Head and Neck
Genomic and transcriptomic alterations in m6A regulatory genes are associated with tumorigenesis and poor prognosis in head and neck squamous cell carcinoma.
LNCAROD is stabilized by m6A methylation and promotes cancer progression via forming a ternary complex with HSPA1A and YBX1 in head and neck squamous cell carcinoma.
METTL3 Facilitates Oral Squamous Cell Carcinoma Tumorigenesis by Enhancing c-Myc Stability via YTHDF1-Mediated m6A Modification.
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
Starvation
Yeast m6A Methylated mRNAs Are Enriched on Translating Ribosomes during Meiosis, and under Rapamycin Treatment.
Stomach Neoplasms
Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
Inhibiting PP2Ac? Promotes the Malignant Phenotype of Gastric Cancer Cells through the ATM/METTL3 Axis.
Knockdown of m6A methyltransferase METTL3 in gastric cancer cells results in suppression of cell proliferation.
m6A Methyltransferase 3 Promotes the Proliferation and Migration of Gastric Cancer Cells through the m6A Modification of YAP1.
METTL3 Promotes the Progression of Gastric Cancer via Targeting the MYC Pathway.
METTL3 Promotes the Proliferation and Mobility of Gastric Cancer Cells.
METTL3-mediated m6A methylation of SPHK2 promotes gastric cancer progression by targeting KLF2.
METTL3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance.
METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
MicroRNA-1269b inhibits gastric cancer development through regulating methyltransferase-like 3 (METTL3).
MiR-4429 prevented gastric cancer progression through targeting METTL3 to inhibit m6A-caused stabilization of SEC62.
N6-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer.
The m6A methyltransferase METTL14 inhibits the proliferation, migration, and invasion of gastric cancer by regulating the PI3K/AKT/mTOR signaling pathway.
YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway.
Testicular Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Thymoma
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
Thymus Neoplasms
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors.
Thyroid Cancer, Papillary
METTL14 promotes tumorigenesis by regulating lncRNA OIP5-AS1/miR-98/ADAMTS8 signaling in papillary thyroid cancer.
METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration.
Thyroid Diseases
METTL3 gene polymorphisms contribute to susceptibility to autoimmune thyroid disease.
Thyroid Neoplasms
Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers.
Progression of Thyroid Carcinoma Is Promoted by the m6A Methyltransferase METTL3 Through Regulating m6A Methylation on TCF1.
Tics
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
Triple Negative Breast Neoplasms
Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.
Reduced Expression of METTL3 Promotes Metastasis of Triple-Negative Breast Cancer by m6A Methylation-Mediated COL3A1 Up-Regulation.
Urinary Bladder Neoplasms
Corrigendum: Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis.
Detailed modeling of positive selection improves detection of cancer driver genes.
Dynamic m6A mRNA methylation reveals the role of METTL3-m6A-CDCP1 signaling axis in chemical carcinogenesis.
Mettl14 inhibits bladder TIC self-renewal and bladder tumorigenesis through N6-methyladenosine of Notch1.
METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221/222 maturation in m6A-dependent manner.
Mutations of METTL3 predict response to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
N6-methyladenosine modification of ITGA6 mRNA promotes the development and progression of bladder cancer.
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
The m6A Methylation-Regulated AFF4 Promotes Self-Renewal of Bladder Cancer Stem Cells.
The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-?B/MYC signaling network.
Urologic Neoplasms
Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers.
Uterine Cervical Neoplasms
Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer.
Elevated Expression of Inhibitor of Apoptosis-stimulating Protein of p53 (iASPP) and Methyltransferase-like 3 (METTL3) Correlate with Poor Prognosis in FIGO Ib1-IIa Squamous Cell Cervical Cancer.
METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE.
METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B.
N6-methyladenosine METTL3 promotes cervical cancer tumorigenesis and Warburg effect through YTHDF1/HK2 modification.
N6-methyladenosine regulates glycolysis of cancer cells through PDK4.
[Knockdown of YTH N6-methyladenosine RNA binding protein 2 (YTHDF2) inhibits cell proliferation and promotes apoptosis in cervical cancer cells].
Vascular Calcification
METTL14-dependent m6A regulates vascular calcification induced by indoxyl sulfate.
miR-33a-5p Suppresses ox-LDL-Stimulated Calcification of Vascular Smooth Muscle Cells by Targeting METTL3.
Vesicular Stomatitis
N6-methyladenosine RNA modification suppresses antiviral innate sensing pathways via reshaping double-stranded RNA.
Virus Diseases
1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors.
m6A modification controls the innate immune response to infection by targeting type I interferons.
Vitreoretinopathy, Proliferative
METTL3 attenuates proliferative vitreoretinopathy and epithelial-mesenchymal transition of retinal pigment epithelial cells via wnt/?-catenin pathway.
Wilms Tumor
Human umbilical cord mesenchymal stem cells deliver exogenous miR-26a-5p via exosomes to inhibit nucleus pulposus cell pyroptosis through METTL14/NLRP3.
m6A mRNA methylation regulates testosterone synthesis through modulating autophagy in Leydig cells.
METTL3 polymorphisms and Wilms tumor susceptibility in Chinese children: A five-center case-control study.
METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells.
N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer.
The contribution of YTHDF2 gene rs3738067 A>G to the Wilms tumor susceptibility.
The RNA m6A writer METTL14 in cancers: Roles, structures, and applications.
The RNA Methyltransferase Complex of WTAP, METTL3, and METTL14 Regulates Mitotic Clonal Expansion in Adipogenesis.
Zika Virus Infection
Dynamics of Human and Viral RNA Methylation during Zika Virus Infection.